Skip to content
TheBrief.Health

OBGYN and women's medicine

Women's Health

Obstetric, gynecologic and women's health evidence across the reproductive lifespan.

Breast cancer pathology slides beside a treatment-planning notebook in an oncology workspace.

Women's Health

Sacituzumab Govitecan Moves Into First-Line TNBC Care

The FDA approved first-line sacituzumab govitecan alone for patients unable to receive checkpoint inhibition and with pembrolizumab for PD-L1–positive advanced triple-negative breast cancer.

Rayan Salih · September 22, 2026 · 7 min

Breast tumor tissue slides beside a pathology request for PD-L1 combined positive score testing.

Women's Health

PD-L1 Testing Defines New First-Line Option in TNBC

The FDA approved first-line sacituzumab govitecan plus pembrolizumab for unresectable or metastatic TNBC with PD-L1 CPS ≥10, making validated biomarker testing pivotal to treatment selection.

Rayan Salih · 7 min read

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.